Alimta

(Pemetrexed disodium)

Phase 3Small molecule

Pemetrexed is used to treat certain types of cancer, including lung cancer and mesothelioma (a cancer caused by asbestos exposure). It works by slowing or stopping the growth of cancer cells in the body.[1] Alimta is currently being investigated across 56 indications[3], with its most advanced program in Phase 3.[1]

Alimta is one of 691 small molecule programs targeting Peritoneum Cancer. It is currently in Phase 3.

Indications

150

Total Trials

Active Trials

690

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peritoneum CancerActive, not recruiting

Gestational Trophoblastic NeoplasmActive, not recruiting

Salivary Gland CancerActive, not recruiting

Lung CancerActive, not recruiting

LymphomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Head and Neck Malignant NeoplasiaActive, not recruiting

Thymic CarcinomaActive, not recruiting

Gallbladder CancerActive, not recruiting

ThymomaActive, not recruiting

Peritoneum CancerPhase 2

Active, not recruiting

Gestational Trophoblastic NeoplasmPhase 2

Active, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Malignant Pleural MesotheliomaPhase 1/Phase 2

Active, not recruiting

Head and Neck Malignant NeoplasiaPhase 2

Active, not recruiting

Thymic CarcinomaPhase 2

Active, not recruiting

Gallbladder CancerPhase 1/Phase 2

Active, not recruiting

ThymomaPhase 2

Active, not recruiting

Showing 10 of 56 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Alimta

GGynecologic Oncology Group

Phase 3

1 2

Prolia

Amgen

Preclinical

14 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05298423

Phase 2Recruiting

Peritoneal Malignant Mesothelioma

NCT05001880

PreclinicalActive, not recruiting

Non-Small Cell Lung Cancer

NCT06624059

Phase 3Recruiting

EGFR-Mutated Locally Advanced or Metastatic NSCLC

NCT06927986

Phase 1Active, not recruiting

Biphasic Mesothelioma

NCT03228537

PreclinicalActive, not recruiting

Lung Non-Small Cell Carcinoma

NCT02194738

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer58 trials

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04379635·453 enrolled

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·N/A·NCT02145078·4 enrolled

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

Show 55 more trials

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 1·NCT01723800·9 enrolled

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00863512·34 enrolled

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03366766·14 enrolled

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00389805·27 enrolled

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00438204·39 enrolled

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00698815·130 enrolled

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Withdrawn·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02607423

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00248495·38 enrolled

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 2·NCT00227539·25 enrolled

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00738881·23 enrolled

Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00280748·10 enrolled

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00117962·109 enrolled

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Terminated·SSWOG Cancer Research Network·Phase 2·NCT02134912·1 enrolled

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00301808·29 enrolled

Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00389688·13 enrolled

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06659042·32 enrolled

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00798603·65 enrolled

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01928160

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00268489·48 enrolled

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Unknown status·IIstituto Scientifico H. San Raffaele·Phase 3·NCT00989690·275 enrolled

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT04061590

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·MMayo Clinic·Phase 2·NCT00407550·19 enrolled

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02535325·17 enrolled

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting·NNRG Oncology·Phase 2·NCT03137771·218 enrolled

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00022646·157 enrolled

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01784640·13 enrolled

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01958372·11 enrolled

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00387322·42 enrolled

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00660816·46 enrolled

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

Completed·WWake Forest University Health Sciences·Phase 2·NCT02426658·16 enrolled

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01935947·17 enrolled

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00410904·60 enrolled

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01664754·8 enrolled

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00454194·110 enrolled

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Completed·SSWOG Cancer Research Network·Phase 2·NCT03971474·166 enrolled

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00950365·79 enrolled

Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01344824·38 enrolled

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00520845·23 enrolled

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06772623·252 enrolled

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Recruiting· Roche logo

Roche·Preclinical·NCT05789082·320 enrolled

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07190248·675 enrolled

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06448754·180 enrolled

A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06711900·432 enrolled

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting· Roche logo

Roche·Phase 3·NCT06793215·600 enrolled

Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06745882·318 enrolled

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02609776·751 enrolled

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06899126·686 enrolled

A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status

Active, not recruiting· Roche logo

Roche·Preclinical·NCT06624059·11 enrolled

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07680790·850 enrolled

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06712316·1,260 enrolled

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02220894·1,274 enrolled

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06561386·1,000 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07100080·500 enrolled

Carcinoma, Non-Small-Cell Lung10 trials

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Recruiting·MMirati Therapeutics Inc.·Phase 3·NCT06875310·630 enrolled

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06119581·1,264 enrolled

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07586202·68 enrolled

Show 7 more trials

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04077463·701 enrolled

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04538664·308 enrolled

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06623422·680 enrolled

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05498428·520 enrolled

A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06008093·103 enrolled

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05298423·611 enrolled

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT04165070·450 enrolled

Malignant Pleural Mesothelioma5 trials

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01105390

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT01064648·117 enrolled

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00227630·59 enrolled

Show 2 more trials

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00101283·32 enrolled

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01085630·72 enrolled

Solid Tumor5 trials

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Recruiting·SSynthekine·Preclinical·NCT05098132·364 enrolled

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting·CCStone Pharmaceuticals·Preclinical·NCT06741644·660 enrolled

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Recruiting· Astellas logo

Astellas·Phase 1·NCT05382559·681 enrolled

Show 2 more trials

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AWT020 Alone and in Combination With Other Antitumor Therapies in Patients With Advanced Malignancies

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06839105·214 enrolled

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Recruiting·MMirati Therapeutics Inc.·Phase 2·NCT07415031·170 enrolled

Lung Non-Small Cell Carcinoma4 trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04267848·1,210 enrolled

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02194738·8,300 enrolled

Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT06632327·1,100 enrolled

Show 1 more trial

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00324805·1,501 enrolled

55 more indications

Patients With Advanced Solid Tumors3 trials

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00390000·29 enrolled

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00703638·16 enrolled

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

Completed·VVirginia Commonwealth University·Phase 1·NCT01450384·37 enrolled

Metastatic Solid Tumors3 trials

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00320073·41 enrolled

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00573690·31 enrolled

Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors

Completed·SSan Antonio Cancer Institute·Phase 1·NCT00003711

Non-small Cell Lung Cancer (NSCLC)3 trials

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06694454·60 enrolled

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06305754·520 enrolled

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT06162221·616 enrolled

Lung Cancer2 trials

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01993810·330 enrolled

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05118854·13 enrolled

Mesothelioma2 trials

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT02535312·30 enrolled

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

Completed·CCentre Oscar Lambret·Phase 2·NCT00541073·60 enrolled

Metastatic Urothelial Cancer2 trials

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting·SShanghai Miracogen Inc.·Phase 3·NCT05754853·290 enrolled

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02693717·7 enrolled

Biphasic Mesothelioma2 trials

Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)

Terminated·NNRG Oncology·Phase 3·NCT04158141·16 enrolled

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03228537·28 enrolled

Lung Cancer, Non-squamous, Non-small Cell2 trials

Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT07486817·60 enrolled

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06151574·428 enrolled

Locally Advanced Lung Non-Small Cell Carcinoma2 trials

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05136846·28 enrolled

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Recruiting·NNRG Oncology·Phase 3·NCT05624996·474 enrolled

Metastatic Non Small Cell Lung Cancer2 trials

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07063745·590 enrolled

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT05555732·1,170 enrolled

Endometrial Cancer1 trial

Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00087100·51 enrolled

Gastric Cancer1 trial

Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy

Completed·SSun Yat-sen University·Phase 2·NCT01953419·34 enrolled

Cervical Cancer1 trial

Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00691301·55 enrolled

Lymphoma1 trial

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00470405·25 enrolled

Locally Advanced Head and Neck Cancer1 trial

Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00503997·42 enrolled

Prostate Cancer1 trial

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Completed·UUniversity of Southern California·Phase 2·NCT01338792·47 enrolled

Advanced Cancer1 trial

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00053209·46 enrolled

Primary Peritoneal Cancer1 trial

Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00087087·51 enrolled

Pregnancy1 trial

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Terminated·GGynecologic Oncology Group·Phase 2·NCT00096187·55 enrolled

Solid Tumors1 trial

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00070473·33 enrolled

Salivary Gland Cancer1 trial

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Active, not recruiting·MMayo Clinic·Phase 2·NCT04895735·45 enrolled

Pancreatic Cancer1 trial

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Terminated·WWake Forest University Health Sciences·Phase 1·NCT00310050·4 enrolled

Recurrent Cancer1 trial

Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix

Completed·GGynecologic Oncology Group·Phase 2·NCT00087113

Ovarian Cancer1 trial

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Completed·UUniversity of Arizona·Phase 1·NCT00702299·15 enrolled

Breast Cancer1 trial

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006007·59 enrolled

Intensity-modulated Radiation Therapy1 trial

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Terminated·WWake Forest University Health Sciences·Phase 1/2·NCT00573989·27 enrolled

Gallbladder Cancer1 trial

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00059865·68 enrolled

Chondrosarcoma1 trial

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00107419·75 enrolled

Malignant Mesothelioma1 trial

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00005636

Fallopian Tube Cancer1 trial

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·—·Phase 2·NCT01001910·22 enrolled

Small Cell Lung Cancer1 trial

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00227565·50 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003706·50 enrolled

Advanced Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT06096844·304 enrolled

Locally Advanced or Metastatic Non-small Cell Lung Cancer1 trial

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05048797·454 enrolled

Malignant Neoplasm1 trial

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07252739·130 enrolled

Solid Tumor, Adult1 trial

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Active, not recruiting·IiOnctura·Phase 1·NCT04328844·210 enrolled

Peritoneal Malignant Mesothelioma1 trial

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05001880·66 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04092283·660 enrolled

Malignant Solid Tumor1 trial

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Active, not recruiting· Genmab logo

Genmab·Preclinical·NCT04083599·350 enrolled

HER2 Mutation1 trial

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Recruiting· Bayer logo

Bayer·Phase 3·NCT06452277·444 enrolled

Non-Small-Cell Lung1 trial

A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03976323·1,003 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

Completed· Incyte logo

Incyte·Phase 3·NCT04205812·583 enrolled

Neoplasms1 trial

An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05112965·49 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03793179·600 enrolled

EGFR-mutated Locally Advanced or Metastatic NSCLC1 trial

A Randomized, Open-label, Multi-center, Phase III Clinical Study Comparing SYS6010 With Platinum-based Chemotherapy in the Treatment of EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of EGFR TKI Treatment

Recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT06927986·380 enrolled

NSCLC1 trial

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting·EEllipses Pharma·Preclinical·NCT05443126·265 enrolled

Non-Squamous Non-Small Cell Lung Cancer1 trial

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06627647·878 enrolled

Advanced Solid Tumor1 trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04649385·157 enrolled

NSCLC, Stage IB-IIIA1 trial

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 3·NCT07128199·360 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06788912·60 enrolled

Carcinoma，Non-Small-Cell Lung1 trial

A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03088540·712 enrolled

Double Blind1 trial

A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting·SSinocelltech Ltd.·Preclinical·NCT07662395·410 enrolled

Advanced Malignancies1 trial

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05059522·77 enrolled

Advanced Solid Tumors1 trial

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05067283·830 enrolled

Unspecified1 trial

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03899155·1,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 150 trial records for Pemetrexed disodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed disodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed disodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GAR Transformylase Inhibitor; Dihydrofolate Reductase Inhibitor; Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

Alimta

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer58 trials

Carcinoma, Non-Small-Cell Lung10 trials

Malignant Pleural Mesothelioma5 trials

Solid Tumor5 trials

Lung Non-Small Cell Carcinoma4 trials

Patients With Advanced Solid Tumors3 trials

Metastatic Solid Tumors3 trials

Non-small Cell Lung Cancer (NSCLC)3 trials

Lung Cancer2 trials

Mesothelioma2 trials

Metastatic Urothelial Cancer2 trials

Biphasic Mesothelioma2 trials

Lung Cancer, Non-squamous, Non-small Cell2 trials

Locally Advanced Lung Non-Small Cell Carcinoma2 trials

Metastatic Non Small Cell Lung Cancer2 trials

Endometrial Cancer1 trial

Gastric Cancer1 trial

Cervical Cancer1 trial

Lymphoma1 trial

Locally Advanced Head and Neck Cancer1 trial

Prostate Cancer1 trial

Advanced Cancer1 trial

Primary Peritoneal Cancer1 trial

Pregnancy1 trial

Solid Tumors1 trial

Salivary Gland Cancer1 trial

Pancreatic Cancer1 trial

Recurrent Cancer1 trial

Ovarian Cancer1 trial

Breast Cancer1 trial

Intensity-modulated Radiation Therapy1 trial

Gallbladder Cancer1 trial

Chondrosarcoma1 trial

Malignant Mesothelioma1 trial

Fallopian Tube Cancer1 trial

Small Cell Lung Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Advanced Lung Non-Small Cell Carcinoma1 trial

Locally Advanced or Metastatic Non-small Cell Lung Cancer1 trial

Malignant Neoplasm1 trial

Solid Tumor, Adult1 trial

Peritoneal Malignant Mesothelioma1 trial

Recurrent Lung Non-Small Cell Carcinoma1 trial

Malignant Solid Tumor1 trial

HER2 Mutation1 trial

Non-Small-Cell Lung1 trial

Non-Small Cell Lung Carcinoma1 trial

Neoplasms1 trial

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

EGFR-mutated Locally Advanced or Metastatic NSCLC1 trial

NSCLC1 trial

Non-Squamous Non-Small Cell Lung Cancer1 trial

Advanced Solid Tumor1 trial

NSCLC, Stage IB-IIIA1 trial

Lung Neoplasm Malignant1 trial

Carcinoma，Non-Small-Cell Lung1 trial

Double Blind1 trial

Advanced Malignancies1 trial

Advanced Solid Tumors1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News